MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 12-14, including online poster presentations and online industry sponsored symposium.
The company will showcase the Personalis NeXT Platform® which enables comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The NeXT Platform™ can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following is a list of abstracts that will be presented online at the meeting.
Scientific Poster Presentations
Poster Number & Category |
Title & Presenter |
Day & Time |
19 Biomarkers, Immune Monitoring, and Novel Technologies |
Presenter: Charles W. Abbott, PhD |
NOV 12 -14 | Online
|
20 Biomarkers, Immune Monitoring, and Novel Technologies |
Presenter: Charles W. Abbott, Ph.D. |
NOV 12 -14 | Online
|
75 Biomarkers, Immune Monitoring, and Novel Technologies |
Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome Presenter: Eric Levy, PhD |
NOV 12 -14 | Online
|
79 Biomarkers, Immune Monitoring, and Novel Technologies |
Presenter: Rachel M. Pyke, PhD |
NOV 12 -14 | Online
|
Following are details of an industry-sponsored symposium which will be presented online at the meeting.
Industry Sponsor Symposium
Presentation Category |
Title & Presenter |
Day & Time |
|
Sponsored Symposia |
Leveraging comprehensive genomic data for diagnostic capabilities and composite biomarker discovery in immunotherapy Presenter: Erin N. Newburn, PhD |
NOV 12 | 1:30 – 2:00 PM EST
|
Personalis will also be exhibiting during the online portion of conference. Representatives will be available online to answer questions about the company’s cancer immunogenomics services.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on LinkedIn and Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
